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Abstract 
-fetoprotein (AFP) is used as a marker for hepatocellular carcinoma (HCC), which is 
influenced by hepatitis. Protein induced vitamin K absence or antagonist II 
(PIVKA-II) is a sensitive diagnostic marker. Changes in these markers after treatment 
may reflect curability and predict outcome. We conducted an analysis of prognosis in 
470 HCC patients who received curative treatments, and examined relationship 
between changes in AFP and PIVKA-II levels after 1-month of treatment in 156 
patients. Subjects were divided into three groups according to changes in both levels: 
1) normal (L) group before treatment, 2) normalization (N) or 3) decreased but still 
above normal level or unchanged (ANU) group after treatment. High AFP and 
PIVKA-II levels were significantly associated with poor tumor-free and overall 
survival. Presence of large size and advanced stage were significantly associated with 
prevalence of DU group. Overall survival in the AFP-L group was significantly better 
than those of other groups and overall survival in PIVKA-II-L and N groups were 
significantly better than those of PIVKA-II-ANU groups. Combination of changes in 
AFP- ANU and PIVKA-II- ANU group showed the worst tumor-free and overall 
survivals. Multivariate analysis identified high pre-treatment levels of AFP and 
PIVKA-II and combination of AFP- ANU and PIVKA-II- ANU as significant 
determinants of poor tumor-free and overall survival, particularly in patients who 
underwent hepatectomy. We conclude that high levels of AFP or PIVKA-II after 
treatment for HCC did not sufficiently reflect curative efficacy of treatment and 
reflected a poor predictor of prognosis in HCC patients. 
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Introduction 
Hepatocellular carcinoma (HCC) is a common malignant disease worldwide following 
an increase of viral hepatitis and steatohepatitis (1, 2) and patient prognosis has 
recently improved thanks to advances in treatment modalities (3, 4). For early 
diagnosis of HCC and estimation of the biological malignant behavior or patient 
prognosis, sensitive tumor markers are necessary. The -fetoprotein (AFP) has been 
used as a classical marker for hepatocellular carcinoma (HCC) (5). However, AFP 
levels are often high in patients with chronic hepatitis or cirrhosis. (6) Protein induced 
by vitamin K absence or antagonist II (PIVKA-II; des-gamma-carboxy prothrombin) 
was proposed as specific markers for the diagnosis of HCC, evaluation of tumor 
aggressiveness and prognosis. (7, 8)  PIVKA-II has been commonly used for the 
diagnosis in HCC in Japan and has been also adopted worldwide since 2000 (9, 10). 
Recently, analysis of the combination of tumor markers was proposed for accurate 
diagnosis of HCC by the Japan Guideline for HCC Diagnosis and Treatment (11, 12). 
Based on our preliminary experience in patients with resectable HCC(13, 14), 
preoperative PIVKA-II is a useful marker for predicting postoperative tumor 
recurrence and prognosis, while AFP does not closely correlate with clinical outcome. 
Furthermore, other reports indicated that normalization of initially high PIVKA-II 
correlated with better prognosis (13, 14). High AFP and PIVKA-II levels are 
associated with tumor recurrence or poor survival after any treatments for HCC and 
these markers might be useful to predict tumor recurrence during the post-treatment 
follow-up (15). As described above, changes in sensitive markers may indicate 
eradication of HCC. In patients with high levels of tumor markers, complete resection 
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or necrosis of HCC should result in normalization of tumor markers within the half 
life of these markers, only a couple of days (14, 16). A few reports, including our 
preliminary studies, indicated that changes of serum levels of AFP and PIVKA-II 
correlate with prognosis (14, 17, 18). However, to date, there is no consensus 
regarding the value of post-treatment evaluation of tumor markers. To understand the 
significance of changes of tumor biomarkers, it is necessary to examine these 
biomarkers in patients who have undergone curative treatments, including 
hepatectomy or complete ablation therapy.  
We hypothesized that: 1) high levels of AFP and PIVKA-II are poor predictors 
of survival of patients with HCC, and 2) these HCC sensitive markers return to normal 
levels immediately after curative treatment of HCC, and 3) that such normalization 
reflects better prognosis. Measurement of one or more of these markers before and 
after treatment should be useful for evaluating the curability of HCC. To test our 
hypothesis, we examined in this retrospective study the AFP and PIVKA-II levels in 
patients with HCC before and shortly after hepatectomy and local ablation therapy. 
We then evaluated the relationship between preoperative levels of these markers as 
well as changes in these markers with tumor relapse and survival.  
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Materials and Methods 
Patient demographics 
Data of 470 patients with HCC were collected. These patients were diagnosed at the 
Division of Surgical Oncology, Department of Radiology and the Department of 
Gastroenterology and Hepatology, Nagasaki University Hospital (NUH) between 
1988 and October 2009. Patients with remnant viable tumor or untreatable tumor after 
treatment were excluded from this study. All hepatic tumors were completely resected 
without macroscopic exposure of the amputated section of the liver. After examination 
at 1-2 months after primary treatment, the patients were followed-up by measuring 
serum levels of AFP and PIVKA-II every 3 months, and enhanced computed 
tomography of the liver was obtained every 6 months for at least the first 5 years after 
hepatectomy to find out tumor recurrence. In 470 patients, changes of these markers at 
1-2months after treatments were examined in 156 patients (33%), which were 
available samples but not randomly selected. 
 The minimum follow-up period after hepatic resection of HCC was 12 months 
(range, 12-178 months). Fifty-one of 470 (11%) patients who survived were lost to 
follow-up, 129 patients died of cancer, 20 patients died of liver-associated diseases 
and 25 patients died of unrelated diseases. Their data were censored at the last date 
because they were not known to be cancer-related death. The 261 (56%) patients 
developed tumor recurrence after treatment. The study design was approved by the 
Ethics Review Board of NUH including collection of data from the medical records, 
which were also obtained from the associated hospitals mentioned above. 
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Measurement of tumor markers 
A 4-mL peripheral blood sample was collected from each patient before and 1-2 
months after treatment. The sample was then centrifuged at 3,000 rpm (1,000  g) for 
10 minutes. PIVKA-II was assayed by an enzyme-linked immunoassay using Eitest ® 
PIVKA-II (Sanko Junyaku Co., Tokyo, Japan). The normal value of AFP for HCC in 
our hospital is less than 20 ng/mL. The reported normal value of PIVKA-II is <40 
mAU/mL (13). As an increase of these markers were correlated with patient prognosis, 
the level of these markers before treatments were divided into 3 groups as : <20ng/mL, 
20-200ng/mL, >200ng/mL for AFP, and <40mAU/mL, 40-400mAU/mL, 
>400mAU/mL for PIVKA-II according to previous study (13, 14). Elevated levels of 
AFP and PIVKA-II were defined as those exceeding the above levels. Patients were 
divided into three groups based on changes in these markers after treatment: 1) both 
markers lower than the above cut-off levels both before and after treatment (the L 
group), 2) normalization of elevated markers (i.e., levels of both markers above the 
cut-off values returned to within the normal range after treatment, the N group), 3) 
marker levels decreased relative to pre-treatment level but were still above the normal 
ranges, or tumor marker was unchanged or increased (the ANU group). Finally, 
combination of changes (the L and N groups vs. the ANU group) in both tumor 
markers was analyzed for patient survivals. 
 The tumor-related factors were related to histopathological examination of the 
resected specimen. For assessment, we used the histopathological factors and 
curability by hepatectomy of the Liver Cancer Study Group of Japan by the 
Classification of Primary Liver cancer (19). 
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Statistical analysis 
Differences in categorical data between groups or prevalence were assessed by the 
chi-square, Fischer’s exact or Dunnet’s multiple comparison tests. Differences in 
continuous data between groups were evaluated by the Student’s t-test or 
Mann-Whitney test. The disease-free interval and overall survival were calculated 
using the Kaplan-Meier method, and differences between groups were tested for 
significance using the log-rank test. Multivariate analysis was performed using Cox’s 
proportional hazards regression modeling. A two-tailed P value of <0.05 was 
considered significant. Statistical analyses were performed using the SAS software 
(Statistical Analysis System Inc., Cary, NC). 
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Results 
Patient demographics 
The mean age of the patients at the time of surgery was 66.4±9.8 years (range, 23-88 
years), and there were 342 males (73%) and 128 females. The background liver 
abnormalities included chronic hepatitis in 187 (40%) patients, cirrhosis in 270 (57%), 
and normal liver in 13 (3%), associated with hepatitis virus B (n=122), hepatitis virus 
C (n=253), both hepatitis B and C (n=19), alcoholic disease (n=6) or others (n=70). 
According to the Child-Pugh classification, 405 (86%) patients were classified as A 
and 65 as B and C. The pathological tumor node metastasis (TNM) stage of HCC 
according to the Liver Cancer Study Group of Japan 21 was stage I in 139 (30%), stage 
II in 196 (42%), stage III in 93 (20%) and stage IVA in 42 (8%). The treatment 
included surgical resection (n=331, 70%), thermal ablation by radio frequency or 
microwave ablation (n=114, 24%), alcohol injection (n=25, 6%). The surgical 
resections included partial hepatic resections (n=322) and whole liver transplantation 
(n=9). 
 
Relationship between preoperative tumor marker levels and incidence of tumor 
recurrence/post-treatment survival 
A significantly high incidence of tumor recurrence and poor tumor-free survival after 
treatment was noted in patients with high pre-treatment levels of AFP and PIVKA-II 
(Table 1 and Fig. 1A). The median recurrence-free survival rate of HCC patients with 
normal AFP level (mean survival period (MSP): 1,754 days) was significantly higher 
than that of patients with high AFP level (p<0.01). Furthermore, the 3- and 5-year 
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tumor-free survival rates of HCC patients with normal AFP level were significantly 
higher than those of patients with high AFP level.  
 The median tumor-free survival rates of HCC patients with normal PIVKA-II 
level (MSP: 1,385 days) and with PIVKA-II level between 40-400 mAU/mL (MSP: 
1,546 days) were significantly higher than that of patients with high PIVKA-II level 
(>400 mAU/mL, MSP: 770 days) (p<0.01). The 3- and 5-year recurrence-free survival 
rates of HCC patients with normal PIVKA-II level or with PIVKA-II level of 40-400 
mAU/mL were significantly higher than those of patients with high PIVKA-II level 
exceeding 400 mAU/mL, respectively (p<0.01).  
 The mean overall survival rates of patients with normal levels of AFP and 
PIVKA-II were significantly higher than that of patients with high levels (Fig. 1B). 
The MSP of HCC patients with normal AFP level was significantly longer than that of 
patients with high AFP levels (p<0.01). The 5- and 8-year overall survival rates of 
HCC patients with normal AFP level were significantly higher than those of patients 
with higher AFP level. The MSP of HCC patients with normal PIVKA-II level and 
those with PIVKA-II level of 40-400 mAU/mL were significantly longer than that in 
patients with high PIVKA-II level >400 mAU/mL (p<0.01). The 5- and 8-year overall 
survival rates of HCC patients with normal PIVKA-II level were significantly higher 
than those of patients with high PIVKA-II level (p<0.01).  
    Figures 2A and B show the differences in disease-free and overall survival for 
each treatment. The hepatectomy group had a better prognosis in comparison with 
ablation therapy. Therefore, we examined the survival analysis associated with 
changes of tumor markers for each treatment. 
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Relationship between clinicopathological parameters and serum level of tumor 
markers or changes in tumor markers 
Among all 470 patients, 229 (51%) and 286 (67%) had higher than normal ranges of 
AFP and PIVKA-II, before treatment, respectively. Serum levels over 200 ng/ml of 
AFP and over 400 mAU/ml were 107 and 129 patients before treatment, respectively. 
With respect to post-treatment changes in AFP level, 60 patients were classified in the 
L group, 49 in the N group and 45 in the ANU group. With respect to post-treatment 
changes in PIVKA-II level, 22 patients were classified in the L group, 68 in the N 
group and 60 in the ANU group. 
    Tables 2 and 3 show the relationship between various clinicopathological 
parameters and changes in tumor markers. Larger tumor size and advanced TNM 
stage were significantly associated with the incidence of ANU groups for both AFP 
and PIVKA-II. The rate of surgical resection was significantly higher in the L and N 
groups of both AFP and PIVKA-II. The percentages of patients who developed tumor 
recurrence according to AFP level were 45% of the L group, 71% of the N group and 
51% of the ANU group. The percentages of patients who developed tumor recurrence 
according to PIVKA-II level were 36% of the L group, 72% patients of the N group 
and 45% of the ANU group. There were no significant differences in these 
distributions between groups with respect to changes in AFP; however, tumor 
recurrence rate in group L of PIVKA-II was significantly lower than those in group N 
or ANU of PIVKA-II.  
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Relationship between disease-free and overall survival rates and changes in 
serum tumor markers 
Tumor-free survival rate according to changes in AFP in the ANU groups was 
significantly lower than those in the L or N group (Fig. 3A)(p<0.05) and tumor-free 
survival rate according to changes in PIVKA-II in the ANU groups tended to be lower 
than those in the L or N group but not statistically significant (Figure 3B). The 
tumor-free survival rate of patients who underwent hepatectomy in the ANU group 
were significantly lower than those in other groups according to changes in AFP but 
not in PIVKA-II (Table 4). However, there were no significant differences in patients 
who underwent thermal ablation. The overall survival rate of the AFP-L group was 
significantly better than those of AFP-other groups (p<0.05) and the overall survival 
rates of the PIVKA-II-L and N groups were significantly better than those of the 
PIVKA-II- ANU group (Fig. 4A and B). In patients who underwent hepatectomy, the 
overall survival rate of the AFP-L group was significantly better than those of 
AFP-other groups (p<0.05) and the overall survival rates of the PIVKA-II-L and N 
groups were significantly better than those of the PIVKA-II- ANU groups (Table 5). 
In patients undergoing thermal ablation, the overall survival rates in the L group was 
significantly better than that in the N or ANU groups according to changes in AFP but 
not in PIVKA-II. 
   By the survival analysis according to combination of changes in AFP and 
PIVKA-II, AFP-L, -N and PIVKA-II-L, -N group showed the best tumor-free 
survivals and AFP- ANU and PIVKA-II- ANU group showed the worst tumor-free 
survivals in all patients (Fig. 5A) (p<0.05). These differences of tumor-free survival 
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tended to be observed in ablation therapy but were not significant (Table 6). 
Regarding overall survival, AFP-LN and PIVKA-II-LN group showed the best 
survivals and AFP- ANU and PIVKA-II- ANU group showed the worst survivals in all 
patients (Table 6) (p<0.05). This tendency was also observed in patients who 
underwent hepatectomy or ablation therapy. There were no significant differences of 
survivals between AFP- ANU and PIVKA-II L, -N vs. AFP-L, -N and 
PIVKA-II-ANU. 
   Table 7 shows the significant prognostic factors, including changes in AFP and 
PIVKA-II levels, for all patients, associated with tumor-free and overall survival rates, 
identified by univariate analysis. With respect to the tumor-free survival rate, multiple 
tumors, large tumor size, advanced tumor stage, poor liver function, pre-treatment 
high AFP or PIVKA-II levels, PIVKA-II- ANU group, and combination of AFP- ANU 
or PIVKA-II- ANU were significantly associated with poor survival based on 
univariate analysis (p<0.05). Multivariate analysis showed that larger tumor size, 
increase in AFP level, high PIVKA-II levels before treatment, and combination of 
AFP- ANU and PIVKA-II- ANU were significantly associated with poor tumor-free 
survival (p<0.05). With respect to overall survival, multiple tumors, large tumor size, 
advanced tumor stage, poor liver function, pre-treatment high levels of AFP or 
PIVKA-II, AFP- ANU group, PIVKA-II- ANU group, combination of AFP- ANU and 
PIVKA-II- ANU, and ablation group were significantly associated with poor overall 
survival (p<0.05). Multivariate analysis showed that larger tumor size, PIVKA-II- 
ANU group, combination of AFP- ANU and PIVKA-II- ANU, and ablation group 
were significantly associated with poor survival (p<0.05).  
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As a difference in overall survival between hepatectomy and ablation therapy 
was observed, the prognostic factors in patients who underwent hepatectomy were 
examined. Table 8 shows the significant prognostic factors, including changes in AFP 
and PIVKA-II levels after hepatectomy, associated with tumor-free and overall 
survival in HCC patients who underwent hepatectomy. With respect to tumor-free 
survival, the presence of multiple tumors, large size tumor, advanced tumor stage, 
viral etiology, poor liver function, and pre-treatment high levels of AFP or PIVKA-II 
were correlated significantly with poor survival (p<0.05). Multivariate analysis 
identified large tumor size, poor liver function, and pre-treatment high levels of AFP 
and PIVKA-II level as significant poor prognostic factors for tumor-free survival. 
With respect to overall survival, the presence of multiple tumors, large tumor size, 
advanced tumor stage, poor liver function, pre-treatment high levels of AFP or 
PIVKA-II, PIVKA-II- ANU group and combination of AFP- ANU and PIVKA-II- 
ANU were significantly associated with poor survival (p<0.05). Multivariate analysis 
identified only advanced tumor stage and poor liver function as significant poor 
prognostic factors for overall survival. 
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Discussion 
Specific HCC markers, such as PIVKA-II or AFP L3 fraction, in combination with 
AFP level, are commonly used in Japan for the diagnosis of HCC or evaluation of 
tumor aggressiveness (6-15,17,18, 20, 21). High values of these markers reflect 
patient prognosis after any treatment (13-15, 17, 18, 22). We previously reported that 
HCC staging including preoperative PIVKA-II level is an independent prognostic 
marker in HCC patients who undergo hepatectomy. (13,23) Monitoring of PIVKA-II 
might be useful for predicting tumor recurrence after hepatectomy at earlier period 
compared to AFP level (24, 25) and our pilot study also showed that changes in 
PIVKA-II significantly correlated with prognosis in a small number of HCC patients 
undergoing hepatectomy. (14) It is possible that sensitive tumor markers return to 
normal levels soon after curative treatment. Therefore, we focused in the present study 
on changes in these markers at an early postoperative period testing a large number of 
HCC patients who were treated by curative treatments to clarify usefulness of these 
markers and their changes. The usefulness of measuring tumor biological markers can 
be evaluated after curative treatments, including hepatectomy or complete ablation 
therapy. In the present results, patient survival between hepatectomy and ablation 
therapy was significantly different and, therefore, we examined survival analysis in 
each treatment. Survival analysis in patients who underwent chemotherapy or other 
palliative treatments were not examined in this study. 
In our pilot study, (14) we excluded HCC patients with normal preoperative levels 
of AFP/PIVKA-II because changes in these markers could not be measured and thus 
their prognosis was not evaluated. In the present study, we examined HCC patients 
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with low and high preoperative levels of both AFP and PIVKA-II. The cut-off levels 
of markers were set up according to the normal range and previous reports on the 
relationship between tumor markers and prognosis in HCC. (5, 7, 8, 13, 14, 26) The 
number of patients with normal preoperative PIVKA-II levels was less than that of 
patients with normal AFP level. This finding suggests that AFP level could reflect 
inflammatory activity associated with chronic hepatitis.(6) The results of the present 
study showed that high preoperative levels of both tumor markers correlated with 
tumor recurrence rate and that HCC patients with high levels of both markers before 
treatment were also associated with poor disease-free and overall survival rates, in 
agreement with previous reports. (15, 17, 18, 27, 28) Furthermore, survival analysis 
showed that a high preoperative level of AFP or PIVKA-II was also associated with 
better survival. Patients with AFP levels of 20-200 and >200 ng/mL had similar 
tumor-free and overall survival rates. On the other hand, the tumor-free and overall 
survival rates of patients with PIVKA-II levels of 40-400 mAU/mL were better than in 
those with levels ≥400 mAU/mL. This result indicates that PIVKA-II level of ≥400 
mAU/mL is a predictor of poor prognosis and that level is more sensitive than AFP in 
predicting tumor recurrence or prognosis.(23-25, 29) In the present study, changes of 
both AFP and PIVKA-II levels were focused to evaluate effectiveness of any 
treatments because half-life of these serum markers was limited within a few 
weeks.(16) We hypothesize that L group showed the lowest malignancies in all groups 
before treatments and, in the N group, the tumor was mostly disappeared by the 
effective treatments. In the ANU group, viable or active HCC might remain and HCC 
of ANU group might be remained and had the most aggressive malignancies in the 
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study design. The results of analysis of relationship with clinicopathological 
parameters showed that advanced HCC and poor liver function correlated with the 
AFP- ANU group. In the AFP- ANU group, remnant liver dysfunction might be 
influenced the high level of postoperative AFP (30) as well as tumor malignancies. 
Poor liver function and active hepatitis might progress to tumor recurrence through 
multicentric carcinogenesis of HCC.(31) Interestingly, changes in PIVKA-II were also 
related to advanced tumors and poor liver function in the present study. The 
relationship between PIVKA-II and liver dysfunction has been examined extensively 
because the metabolism of vitamin K is to a large extent dependent on liver 
function.(32) Our results showed that changes in PIVKA-II levels after treatment 
tended to reflect tumor recurrence, compared with changes in AFP level. This finding 
suggests that analysis of PIVKA-II at follow-up is more reliable for prediction of 
tumor recurrence after treatment compared with AFP. While, Nobuoka et al. reported 
that postoperative AFP level is useful to predict recurrence after hepatectomy by 
comparison with postoperative PIVKA-II level.(33) 
 Univariate analysis of data of all patients on changes in both tumor markers 
showed no difference in tumor-free survival rate, irrespective of treatment modality. 
With respect to overall survival, HCC patients of the AFP- and PIVKA-II-L groups 
had the best prognosis while multivariate analysis showed that patients of the 
PIVKA-II- ANU group had the poorest survival. This tendency was similar in HCC 
patients undergoing hepatectomy. However, multivariate analysis did not identify 
changes in PIVKA-II as a significant prognostic factor. On the other hand, tumor-free 
survival correlated significantly with high baseline PIVKA-II levels. In this regard, a 
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previous study reported that normalization of PIVKA-II correlated with good 
prognosis.(14) While, Nobuoka et al. stressed the significance of postoperative AFP in 
relation to posttreatment recurrence of HCC.(34), Kanazumi et al. reported that serum 
PIVKA-II level decreased within 2 weeks after effective surgery (25) and suggested 
that PIVKA-II level higher than the normal range might reflect remnant HCC. In the 
present study, we speculated that normalization of PIVKA-II could reflect a 
satisfactory outcome with cure of HCC based on the result of survival analysis. 
Considered together with the results of the present study, we propose that patients with 
high PIVKA-II levels after hepatectomy (e.g., patients of the PIVKA-II- ANU groups) 
should receive adjuvant therapy to control invisible remnant HCC cells, to improve 
survival. By results of AFP and PIVKA-II, we attempted to combine both markers for 
survival analysis. Eventually, combination of AFP- ANU and PIVKA-II- ANU was 
the worst predictor of tumor-free and overall survivals, respectively. In case of 
diagnosis for HCC, combination of AFP and PIVKA-II was recommended to diagnose 
tumor malignancy by the Japan's guideline for HCC at present.(12) Recent studies 
showed that AFP L3 fraction is a better specific marker for HCC than AFP level.(11, 
35) However, since the significance of AFP L3 fraction has not yet been clarified, (36) 
it is necessary to examine this marker for better assessment of patient prognosis.  
 For HCC patients who underwent thermal ablation, changes in AFP and 
PIVKA-II also tended to be associated with tumor-free and overall survival rates. 
Pretreatment AFP or PIVKA-II levels were associated with survival, though such 
correlation could not be confirmed by multivariate analysis. Previous studies also 
showed that high levels of AFP and PIVKA-II were associated with survival.(7,8, 
Nanashima et al., Page 19 
13-15, 17, 18,21-23) Thus, in HCC patients with high levels of AFP or PIVKA-II 
level, hepatectomy is a better therapeutic choice especially for those patients with 
preserved liver function because hepatectomy is the best treatment modality 
associated with longer survival compared with other treatment modalities, with the 
exception of liver transplantation.(37) 
 In summary, we conducted a retrospective analysis of prognosis of 470 HCC 
patients who received curative treatments, including hepatectomy and ablation therapy, 
including analysis of the relationship between changes in AFP and PIVKA-II after 
treatment and patient survival in 156 patients. Compared to changes in AFP, 
preoperative low levels of PIVKA-II and their normalization after treatment were 
significantly associated with better survival after hepatectomy based on multivariate 
analyses, particularly in patients who underwent hepatectomy. Normalization of 
PIVKA-II levels after treatment reflects the efficacy of the treatment and is a suitable 
predictor of prognosis in patients who underwent curative treatment for HCC. Careful 
follow-up and adjuvant chemotherapy is necessary for patients who fail to show 
normalization of tumor markers at the early period after treatment. 
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Fig. 1 Post-treatment tumor-free (A) and overall (B) survival rates for each level of 
preoperative AFP and PIVKA-II.  
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Fig.2 Disease-free and overall survival rates for each treatment modality in the 
surgical resection and local ablation groups. 
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Fig. 3 Disease-free survival rates and mean survival period (MSP) after treatment of 
HCC according to the three different patterns of changes in levels of tumor markers 
AFP (A) and PIVKA-II (B). L: both markers lower than the above cut-off levels both 
before and after treatment. N: normalization of elevated markers (i.e., levels of both 
markers above the cut-off values before treatment and returned to within the normal 
range after treatment, the group). ANU: marker levels decreased relative to 
pre-treatment level but were still above the normal ranges, or the levels of tumor 
markers was unchanged after treatment. 
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Fig. 4 Overall survival rates after treatment of HCC according to the different patterns 
of changes in levels of tumor markers AFP (A) and PIVKA-II (B). For definition of 
the different groups, see Figure 3. 
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Fig. 5 Disease-free and overall survival rates after all treatment for HCC according to 
the different combined patterns of changes in levels of AFP and PIVKA-II. For 
definition of the different groups, see Figure 3. 
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Table 1 Relationship between pretreatment AFP or PIVKA-II and posttreatment tumor 
recurrence. 
 














































 AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K antagonist or 
agonist 
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Table 2 Relationship between postoperative changes in AFP and patient demographics, 
clinicopathological parameters and post-treatment tumor recurrence. 
 







Gender (male / female) 
Age 
PIVKA-II (mAU/ml)  
Child-Pugh (A / B/ C) 
Viral status (None / B / C / B&C) 
Number of tumors (solitary/multiple) 
Tumor size (<2/2-5/≥5 cm) 
Japan TNM classification (1/2/3/4a) a 
Treatment 
Surgery/ Thermal ablation  
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Table 3 Relationship between postoperative changes in PIVKA-II and patient demographics, 
clinicopathological parameters and post-treatment tumor recurrence. 
 









AFP (ng/ml) (median) 
Child-Pugh (A / B/ C) 
Viral status (None / B / C / B&C) 
Number of tumors (solitary/multiple) 
Tumor size (<2/2-5/ ≥5 cm) 
Japan TNM classification (1/2/3/4a) 
Treatments 
Surgery/ Thermal ablation  
Tumor recurrence (no/yes) 
15/7 











































For abbreviations, see Table 1. 
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Table 4 Three- and five-year disease-free survival rates between groups of hepatectomy and 
thermal ablation for HCC according to the different patterns of changes in levels of tumor 
markers AFP and PIVKA-II.  
 







3- years  5- years 
Hepatectomy 
  L  group 
  N  group 

















  L  group 
  N  group 
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  N  group 
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  N  group 
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Table 5 Five- and eight-year overall survival rates between groups of hepatectomy and 
thermal ablation for HCC according to the different patterns of changes in levels of tumor 
markers AFP and PIVKA-II.  
 




(P value) 3- years  5- years 
Hepatectomy 
  L  group 
  N  group 

















  L  group 
  N  group 



















  L  group 
  N  group 
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  N  group 
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Table 6 Disease-free and overall survival rates between groups of hepatectomy and thermal 
ablation for HCC according to the different patterns of combination of changes in levels of 
tumor markers AFP and PIVKA-II.  
 




(P value) 3- years  5- years 
Hepatectomy 
  AFP-L-N,PIVKA-II-L-N 
  AFP-ANU,PIVKA-II-L-N 
  AFP-L-N,PIVKA-II-ANU 




















  AFP-L-N,PIVKA-II-L-N 
  AFP-ANU,PIVKA-II-L-N 
  AFP-L-N,PIVKA-II-ANU 



















     




(P value) 5- years  8- years 
Hepatectomy 
  AFP-L-N,PIVKA-II-L-N 
  AFP-ANU,PIVKA-II-L-N 
  AFP-L-N,PIVKA-II-ANU 




















  AFP-L-N,PIVKA-II-L-N 
  AFP-ANU,PIVKA-II-L-N 
  AFP-L-N,PIVKA-II-ANU 
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Table 7 Multivariate analysis by Cox’s proportional hazard test of prognostic factors influencing tumor-free survival and overall survival 
Variable Tumor-free survival Overall survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
RR* (95%CI) P value RR (95%CI) P value RR (95%CI) P value RR (95%CI) P value 
Number of tumors (solitary/multiple)  
Size of tumor 
<2 cm 
2-5 cm 
≥5 cm  












  A 

















Combination of changes of AFP and PIVKA-II 
    AFP-L-N and PIVKA-II-L-N 
    AFP-ANU and PIVKA-II-L-N 
    AFP-L-N and PIVKA-II-ANU 
    AFP-ANU and PIVKA-II-ANU 
Treatment 
    Hepatectomy 



















































































































































































































































































































































* Risk ratio. For abbreviations, see Table 1. 
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Table 8 Multivariate analysis by Cox’s proportional hazard test of prognostic factors influencing tumor-free survival and overall survival in 
patients who underwent hepatectomy 
Variable Tumor-free survival Overall survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
RR* (95%CI) P value RR (95%CI) P value RR (95%CI) P value RR (95%CI) P value 
Number of tumor 
solitary 
multiple  


































Combination of changes of AFP and PIVKA-II 
    AFP-L-N and PIVKA-II-L-N 
    AFP-ANU and PIVKA-II-L-N 
    AFP-L-N and PIVKA-II-ANU 








































































































































































































































































































































* Risk ratio. For abbreviations, see Table 1. 5 
